Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Dolutegravir/Lamivudine in Treatment-Naïve Pregnant Women (PREDUAL)

27. maj 2026 opdateret af: Maria Ines Figueroa, Fundación Huésped

Evaluating the Efficacy and Safety of Dolutegravir/Lamivudine (DTG/3TC) in ART-Naïve Pregnant Women

Protocol Number: FH-94

Study Objetives:

Primary:

  • To evaluate the virological response to Dolutegravir/Lamivudine in naive pregnant women with HIV who are starting antiretroviral therapy and vertical transmission in exposed neonates.

Secondary:

  • To evaluate the incidence of maternal adverse events.
  • To evaluate perinatal outcomes at delivery.
  • To evaluate maximum virological suppression at delivery.
  • To evaluate the incidence of changes in body weight exceeding what is expected for gestation.
  • To evaluate the immune response based on changes in CD4, CD8, and CD4/CD8 ratio values during pregnancy.
  • Assess baseline resistance and the development of resistance to virological failure to integrase inhibitors and INTRs during treatment with DTG+3TC or DTG+TDF/XTC or DTG+TAF/FTC.
  • To evaluate the incidence of HIV infection in children that breastfeed.
  • To evaluate safety outcomes and virological response of DTG+3TC compared to DTG+TDF/XTC or DTG+TAF/FTC.

Exploratory:

  • To explore the non-inferiority of DTG+3TC therapy compared to DTG+TDF/XTC or DTG+TAF/FTC treatment.
  • To evaluate the frequency of antiretroviral therapy withdrawal or modification before delivery.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

Primary endpoints:

  • Proportion of pregnant women who achieve an HIV-1 plasma viral load <200 copies/mL at delivery after starting DTG+3TC (Intention-to-Treat Exposed analysis).
  • Proportion of children born without HIV infection at 6 weeks & 6 months of age, defined by the negative result of negative virological tests (PCR) performed at birth (delivery visit and up to 72 hours after delivery), at 6 weeks, and at 6 months

Secondary endpoints:

  • Frequency of grade 2 or higher maternal adverse events, by type and severity, from baseline to 6 months postpartum.
  • Frequency of spontaneous abortion, preterm delivery, congenital malformations at birth or identified and reported during the first 6 month of life, or intrauterine fetal death.
  • Proportion of pregnant women with plasma viral load below 50 copies/mL at delivery.
  • Average total weight gain and BMI during pregnancy, compared with recommendations based on pre-pregnancy BMI.
  • Changes in CD4 lymphocyte count and CD4/CD8 ratio between baseline and delivery visit values.
  • Frequency and type of mutations according to the International AIDS Society (IAS-USA drug resistance mutations, 2025) mutation guidelines panel at the baseline visit and in case of virological failure at any time during the study.
  • Proportion of HIV infection among breastfed children.
  • Frequency of grade 2 or higher maternal adverse events, by type and severity, between the two arms. Frequency of pregnant women with plasma viral load <200 copies/mL in the two arms at delivery visit.

Exploratory endpoints:

  • Difference in the proportion of pregnant women who achieve an HIV-1 plasma viral load of less than 50 copies/mL at delivery between the DTG+3TC and DTG+TDF/XTC or DTG+TAF/FTC groups, to explore the non-inferiority of the dual regimen.
  • Proportion of participants requiring a change in antiretroviral regimen (due to lack of efficacy, adverse events, medical decision, or other reasons) before delivery.

Patient Population: HIV-1-infected Pregnant Women aged >16 years (>15 years for Brazil's sites) who are naïve to antiretroviral therapy Study design: Phase IV. Randomized, non-comparative, open-label, multicenter study.

Regimens: Dolutegravir 50 mg /lamivudine 300 mg QD FDC. Dolutegravir 50 mg QD plus tenofovir 300 mg/emtricitabine 200mg or plus tenofovir 300 mg/ lamivudine 300 mg or tenofovir alafenamide 25 mg/emtricitabine 200 mg.

Duration: 14 months approximately months (depending on gestational age at entry).

Sample size: 210 subjects

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

210

Fase

  • Fase 4

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Undersøgelse Kontakt Backup

Studiesteder

  • Argentina
    • Buenos Aires
      • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1155AHD
        • Hospital General de Agudos Dr. Cosme Argerich
        • Kontakt:
        • Ledende efterforsker:
          • Diego Cecchini, MD
      • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1188AAF
        • Sanatorio Güemes
        • Kontakt:
        • Kontakt:
          • Sebastián Nuñez, MD
          • Telefonnummer: 8384 / 8365 +54 11 4959-8200
          • E-mail: snunez@fsg.edu.ar
        • Ledende efterforsker:
          • Verónica Lacal, MD
      • Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, C1425AGP
      • El Palomar, Buenos Aires, Argentina, B1684
        • Hospital Nacional Profesor Alejandro Posadas
        • Kontakt:
        • Ledende efterforsker:
          • Mariana Golikow, MD
      • Isidro Casanova, Buenos Aires, Argentina, B1765
        • Hospital de Agudos Paroissien
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Pablo Garnica, MD
  • Brasilien
    • Estado de Bahia
      • Salvador, Estado de Bahia, Brasilien, 40110-160
        • Fundação Bahiana de Infectologia
        • Kontakt:
        • Kontakt:
        • Ledende efterforsker:
          • Carlos Brites, MD
    • Pernambuco
      • Curitiba, Pernambuco, Brasilien, 80430-000
        • Complexo do Hospital de Clínicas da UFPR/Ebserh
        • Kontakt:
        • Ledende efterforsker:
          • Monica Maria Gomes da Silva, MD
    • Rio Grande do Norte
      • Natal, Rio Grande do Norte, Brasilien, 59075-070
        • Universidade Federal do Rio Grande do Norte
        • Kontakt:
        • Ledende efterforsker:
          • Monica Bay, MD
    • Rio de Janeiro
      • Nova Iguaçu, Rio de Janeiro, Brasilien, 26030-380
        • Hospital Geral de Nova Iguaçu
        • Kontakt:
        • Ledende efterforsker:
          • Aline Santos Ramalho Teixeira Benevenuto, MD
    • São Paulo
      • São Paulo, São Paulo, Brasilien, 04037-030
        • RDSS - Ricardo Sobhie Diaz & Cia Solucoes Cientificas Ltda - Ricardo Diaz Scientific Solution
        • Kontakt:
        • Ledende efterforsker:
          • Ricardo Sobhie Diaz, MD

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

All persons who are eligible must meet all of the following:

  1. Confirmed HIV-1 infection: All tests must use blood, serum, or plasma samples. Documentation may be obtained from medical records. HIV-1 positive is defined as having HIV-1 RNA in plasma ≥ 1000 copies/mL, plus one antibody test or two positive HIV antibody tests (two different rapid tests or one rapid test and one positive ELISA/EIE test). If any of these diagnostic test results are not available, they will be performed at the SCR visit. In all cases, an HIV viral load test will be performed.
  2. Not exposed to prior antiretroviral therapy (ART): No prior antiretroviral therapy, including exposure to PrEP and/or PEP in the last 6 months.
  3. Ability to sign the informed consent form.
  4. Plasma HIV-1 RNA ≥1000 copies/mL. Viral load from the last 30 days may be valid. . Age ≥ 16 years or older in Argentina, ≥ 15 years or older in Brazil. The participant must be of the age required in their country of residence to give legal informed consent. Otherwise, informed consent must be signed by a parent or legal guardian, according to country guidelines, in addition to the participant.

6. Pregnant at any gestational age up to 32 weeks at the time of the screening visit: Viable pregnancy with a gestational age ≤32 weeks, defined according to menstrual history and/or ultrasound. Note: If the menstrual history is unknown or if there is a discrepancy between the menstrual history and the ultrasound, the gestational age will be determined based on the best technology available at each center.

7. The participant intends to continue with the pregnancy.

Exclusion Criteria:

All eligible individuals must NOT meet any of the following criteria:

  1. Documented resistance to 3TC (presence of the M184V/I mutation) or DTG (defined as the presence of G118R, Q148 H/K/R, or R263K).
  2. Active hepatitis C infection. 3. Active hepatitis B (HBsAg positive or detectable HBV viral load in cases with isolated positive HBV anti-core).
  3. Hemoglobin <8 g/dL.
  4. Fetal abnormalities detected on ultrasound
  5. Concomitant medications required with possible drug interactions specified in section 5.10.
  6. ALT >=5 times the ULN, or ALT >=3xULN and bilirubin >=1.5xULN (with >35% direct bilirubin). Participants with severe hepatic impairment (Class C) as determined by Child-Pugh classification
  7. Presence of severe preeclampsia or other pregnancy-related events, in current or previous pregnancies, such as renal or hepatic abnormalities (grade 2 or higher proteinuria, elevated serum creatinine, CrCl <50 mL/min, total bilirubin, ALT, or AST).
  8. Active opportunistic infection at screening: active severe opportunistic infections and/or severe bacterial infection, including active tuberculosis or severe disease or unstable clinical condition within 14 days prior to study entry.
  9. Any patient or disease-related condition that, in the investigator's opinion, would prevent the patient from adhering to study medication or complying with study visits or procedures.
  10. Problematic drug and/or alcohol use, which in the opinion of the site investigator could interfere with therapeutic compliance with study requirements.
  11. Known allergy or sensitivity to any of the study medications or their formulations.
  12. Vomiting or any other reason generating inability to swallow medications due to a pre-existing active disorder that prevents proper swallowing and absorption of study medications.
  13. Creatinine Clearance of <30 mL/min . If a creatinine value was obtained within 30 days prior to the screening visit, it may be used to calculate the CrCl.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Experimental
Dolutegravir plus Lamivudine DOVATO: Dolutegravir 50mg/lamivudine 300 mg, FDC, 1 coformulated tablet QD
Medicin: Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]
1 pill QD
Andre navne:
  • BI-THERAPY
Aktiv komparator: Active Comparator

TDF/XTC or TAF/FTC plus Dolutegravir (XTC stands for lamivudine OR emtricitabine)

  • TDF/FTC 300/200 mg, 1 coformulated tablet QD (FDC) plus Dolutegravir 50 mg, 1 tablet QD OR
  • TDF/3TC 300/300 mg, 1 coformulated tablet QD (FDC) plus Dolutegravir 50 mg, 1 tablet QD
  • TAF/FTC 25/200 MG, 1 tablet QD (FDC) plus Dolutegravir 50 mg, 1 tablet QD
Medicin: TDF/XTC or TAF/FTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine)
1 pill of each QD
Andre navne:
  • Tredobbelt terapi

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
To evaluate the virological response to Dolutegravir/Lamivudine in pregnant women with HIV who are starting antiretroviral therapy and vertical transmission in exposed neonates
Tidsramme: From enrollment to the end of treatment at 6 months after delivery

Endpoints:

  • Proportion of pregnant women who achieve an HIV-1 plasma viral load <200 copies/mL at delivery after starting DTG+3TC (Intention-to-Treat Exposed analysis).
  • Proportion of children born without HIV infection at 6 weeks & 6 months of age, defined by the negative result of negative virological tests (PCR) performed at birth (delivery visit and up to 72 hours after delivery), at 6 weeks, and at 6 months.
From enrollment to the end of treatment at 6 months after delivery

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
- To evaluate the incidence of adverse maternal events.
Tidsramme: From enrollment to the end of treatment at 6 months after delivery
Frequency of grade 2 or higher maternal adverse events, by type and severity, from baseline to 6 months postpartum
From enrollment to the end of treatment at 6 months after delivery
- To evaluate perinatal outcomes at delivery
Tidsramme: From enrollment to the end of treatment at 6 months after delivery
Frequency of spontaneous abortion, preterm delivery, congenital malformations at birth or identified and reported during the first 6 month of life, or intrauterine fetal death.
From enrollment to the end of treatment at 6 months after delivery
- To evaluate maximum virological suppression at delivery
Tidsramme: From enrollment to the end of treatment at 6 months after delivery
Proportion of pregnant women with plasma viral load below 50 copies/mL at delivery.
From enrollment to the end of treatment at 6 months after delivery
- To evaluate the incidence of changes in body weight exceeding what is expected for gestation
Tidsramme: From enrollment to the end of treatment at 6 months after delivery
Average total weight gain and BMI during pregnancy, compared with recommendations based on pre-pregnancy BMI.
From enrollment to the end of treatment at 6 months after delivery
- To evaluate the immune response based on changes in CD4, CD8, and CD4/CD8 ratio values during pregnancy.
Tidsramme: From enrollment to the end of treatment at 6 months after delivery
Changes in CD4 lymphocyte count and CD4/CD8 ratio between baseline and delivery visit values.
From enrollment to the end of treatment at 6 months after delivery
- Assess baseline resistance and the development of resistance to virological failure to integrase inhibitors and INTRs during treatment with DTG+3TC, DTG+TDF/XTC or DTG+TAF/FTC.
Tidsramme: From enrollment to the end of treatment at 6 months after delivery
Frequency and type of mutations according to the International AIDS Society (IAS-USA drug resistance mutations, 2025) mutation guidelines panel at the baseline visit and in case of virological failure at any time during the study.
From enrollment to the end of treatment at 6 months after delivery
- To evaluate the incidence of HIV infection in children that breastfeed.
Tidsramme: From enrollment to the end of treatment at 6 months after delivery
Proportion of HIV infection among breastfed children
From enrollment to the end of treatment at 6 months after delivery
To evaluate safety outcomes and virological response of DTG+3TC compared to DTG+TDF/XTC or DTG+TAF/FTC. Part 1 of 2.
Tidsramme: From enrollment to the end of treatment at 6 months after delivery
Frequency of grade 2 or higher maternal adverse events, by type and severity, between the two arms.
From enrollment to the end of treatment at 6 months after delivery
To evaluate safety outcomes and virological response of DTG+3TC compared to DTG+TDF/XTC or DTG+TAF/FTC. Part 2 of 2
Tidsramme: From enrollment to the end of treatment at 6 months after delivery
Frequency of pregnant women with plasma viral load <200 copies/mL in the two arms at delivery visit
From enrollment to the end of treatment at 6 months after delivery

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
- To explore the non-inferiority of DTG+3TC therapy compared to DTG+TDF/XTC or DTG+TAF/FTC treatment.
Tidsramme: From enrollment to the end of treatment at 6 months after delivery
Difference in the proportion of pregnant women who achieve an HIV-1 plasma viral load of less than 50 copies/mL at delivery between the DTG+3TC and DTG+TDF/XTC or DTG+TAF/FTC groups, to explore the non-inferiority of the dual regimen.
From enrollment to the end of treatment at 6 months after delivery
- To evaluate the frequency of antiretroviral therapy withdrawal or modification before delivery.
Tidsramme: From enrollment to the end of treatment at 6 months after delivery
Proportion of participants requiring a change in antiretroviral regimen (due to lack of efficacy, adverse events, medical decision, or other reasons) before delivery
From enrollment to the end of treatment at 6 months after delivery

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Fundación Huésped

Samarbejdspartnere

ViiV Healthcare

Efterforskere

  • Ledende efterforsker: Pedro Enrinque Cahn, MD, Fundación Huésped

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

15. juni 2026

Primær færdiggørelse (Anslået)

15. juli 2028

Studieafslutning (Anslået)

15. september 2028

Datoer for studieregistrering

Først indsendt

14. maj 2026

Først indsendt, der opfyldte QC-kriterier

27. maj 2026

Først opslået (Faktiske)

1. juni 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

1. juni 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

27. maj 2026

Sidst verificeret

1. maj 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • FH-94

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

JA

IPD-delingstidsramme

3 month after last patient last visit

IPD-delingsadgangskriterier

By request

IPD-deling Understøttende informationstype

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med HIV-1-infektion

Kliniske forsøg med Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO]

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Malawi

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner